BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37661807)

  • 21. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
    Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
    Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
    Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
    Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
    Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
    Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity.
    Williamson SR; Hes O; Trpkov K; Aggarwal A; Satapathy A; Mishra S; Sharma S; Sangoi A; Cheng L; Akgul M; Idrees M; Levin A; Sadasivan S; San Miguel Fraile P; Rogala J; Comperat E; Berney DM; Bulimbasic S; McKenney JK; Jha S; Sampat NY; Mohanty SK
    Histopathology; 2023 Jan; 82(2):296-304. PubMed ID: 36208048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex.
    Williamson SR; Hornick JL; Eble JN; Gupta NS; Rogers CG; True L; Grignon DJ; Cheng L
    Hum Pathol; 2018 May; 75():10-15. PubMed ID: 29180251
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Zhang KJ; Qu Z; Pszenica E; Hafron JM; Zhang PL; Brown RE
    Ann Clin Lab Sci; 2023 Jan; 53(1):3-13. PubMed ID: 36889765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinicopathological and molecular genetic characteristics of ELOC mutated renal cell carcinoma].
    Wen Z; Zhang WH; Liang JY; Chai J; Wang YM; Xu WN; Wang Z; Fan LN
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1204-1209. PubMed ID: 38058035
    [No Abstract]   [Full Text] [Related]  

  • 29. Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
    Cox R; Vang R; Epstein JI
    Am J Surg Pathol; 2014 May; 38(5):713-8. PubMed ID: 24441657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
    Baniak N; Flood TA; Buchanan M; Dal Cin P; Hirsch MS
    Histopathology; 2020 Oct; 77(4):659-666. PubMed ID: 32639054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
    Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
    Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sclerosing TSC1 mutated renal cell carcinoma: An unusual pattern mimicking MITF family translocation renal cell carcinoma.
    Williamson SR; Cardili L; Whiteley LJ; Sanchez J; Kis O
    Genes Chromosomes Cancer; 2020 Oct; 59(10):591-594. PubMed ID: 32418252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
    Gupta R; Balzer B; Picken M; Osunkoya AO; Shet T; Alsabeh R; Luthringer D; Paner GP; Amin MB
    Am J Surg Pathol; 2009 Feb; 33(2):241-7. PubMed ID: 18941400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK.
    Wu H; He D; Biswas S; Shafiquzzaman M; Zhou X; Charron J; Wang Y; Nayak BK; Habib SL; Liu H; Li B
    Cancer Res; 2021 Jun; 81(12):3174-3186. PubMed ID: 33863779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
    Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
    Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
    Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T
    Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC -associated Renal Cell Carcinoma.
    Argani P; Matoso A; Pallavajjalla A; Haley L; Tseh-Lin M; Ng J; Chow CW; Lotan T; Mehra R
    Am J Surg Pathol; 2022 Nov; 46(11):1554-1561. PubMed ID: 35941720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.